Presentations & Webinars

Iomab-B Phase 3 Oral Presentation at ASH 2018

Dec 5, 2018

CD33 Program Update – Actimab-A Post Phase 2 Results and Actimab-MDS Regulatory Update

Oct 26, 2018

Company Update - Next Generation Lymphodepletion Technology for CAR-T Conditioning

Sep 26, 2018

Iomab-B DMC Update Conference Call

Aug 15, 2018

Actimab-A MRD clinical trial for Minimal Residual Disease in Postremission AML Patients Webcast

Jul 10, 2018

CD33 Program Expansion: Actimab-A + CLAG-M Conference Call

Feb 13, 2018

ASH 2017 Actimab-A Preliminary Phase 2 Results

Dec 14, 2017

ASH 2017 AWE Platform Results with Daratumumab

Dec 14, 2017

Webcast to Introduce New Clinical Initiative in Collaboration with Leading Hematologist Dr. Gail Roboz

Dec 5, 2017

Webinar Focused on Actimab-A and Recent Developments Related to CD33 Targeted AML Therapies

Jul 13, 2017

• « Previous
• 1
• 2
• 3
• Next »